Celcuity Soars 17.16% on New Patent for Breast Cancer Drug

On July 14, 2025, Celcuity's stock surged by 17.16% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.

Celcuity has recently secured a new U.S. patent (No. 12,350,276) for the clinical dosing regimen of gedatolisib, its lead drug candidate for ER+/HER2- breast cancer. This patent extends the company's exclusivity in the U.S. until 2042, reflecting Celcuity's commitment to enhancing its intellectual property portfolio.

The new patent is part of Celcuity's broader strategy to strengthen its position in the market. With 13 granted gedatolisib-related patents in the U.S. and 290 patents globally, the company is well-positioned to capitalize on the growing demand for innovative cancer treatments.

This development has been met with enthusiasm from investors, who see the extended patent exclusivity as a significant advantage. The patent not only protects Celcuity's lead drug candidate but also opens up new opportunities for the company to explore further advancements in cancer treatment.